ECM and Blood Components for Wound Healing

NCT ID: NCT01909908

Last Updated: 2016-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM) and autologous blood products in wound healing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcer Venous Ulcer Foot Ulcer, Diabetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ECM in Saline

Group Type EXPERIMENTAL

ECM

Intervention Type DEVICE

ECM in saline applied to wound

Blood Products

Group Type ACTIVE_COMPARATOR

Blood Products

Intervention Type BIOLOGICAL

Autologous blood product applied to wound, with saline cleanse on alternating weeks

ECM in Blood Products

Group Type EXPERIMENTAL

ECM in Blood Products

Intervention Type DEVICE

Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECM

ECM in saline applied to wound

Intervention Type DEVICE

Blood Products

Autologous blood product applied to wound, with saline cleanse on alternating weeks

Intervention Type BIOLOGICAL

ECM in Blood Products

Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 or Type 2 diabetes, and/or venous insufficiency to the affected leg
* Ulcer has been present between 12 and 52 weeks
* Ulcer is less than 40 cm2 in area

Exclusion Criteria

* Less than 18 years of age
* Pregnant or planning to become pregnant during the study period
* Simultaneously participating in another investigational drug or device study
* Unable or unwilling to comply with the weekly study follow-up schedule or off-loading regimen
* Patient or legal representative refuses to sign the EC-approved informed consent form
* Known allergy to pig or porcine products
* Additional criteria may apply
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cook Group Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Embil, MD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Health Sciences Centre

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12-014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.